Hvsen Biotechnology Co., Ltd.

SZSE:300871.SZ

14.16 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

2025 Q12024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q3
Revenue 399.069407.775356.25227.161204.501328.373242.304218.67230.412351.422274.46191.353205.666250.307210.17222.239313.5281.082209.553151.821135.002158.86786.962
Cost of Revenue 301.384342.1308.89204.352159.934261.74195.988174.036174.702266.031213.392156.554164.18211.772155.857148.369209.497180.089132.48994.15282.85896.7456.494
Gross Profit 97.68565.67547.35922.80944.56766.63346.31644.63455.7185.39161.06834.79941.48638.53554.31373.87104.003100.99377.06357.6752.14462.12730.469
Gross Profit Ratio 0.2450.1610.1330.10.2180.2030.1910.2040.2420.2430.2230.1820.2020.1540.2580.3320.3320.3590.3680.380.3860.3910.35
Reseach & Development Expenses 14.37816.84412.4919.77314.53513.39111.9669.9549.2862.358.2097.9269.75418.76912.989.2245.91512.616.5795.5483.6455.7834.793
General & Administrative Expenses 14.905-40.68746.5-13.37918.413-41.5146.039-10.50916.52512.66435.255-7.9313.562-13.00220.5941.8917.845-9.0259.793-1.1255.284-42.1655.323
Selling & Marketing Expenses 17.052-16.54229.08814.65914.34214.76614.58113.22213.05915.37711.6589.1812.192.84813.06915.62715.6118.89312.09711.3410.22610.9338.22
SG&A 31.957-57.2375.58720.58428.581-26.74560.6212.71229.58436.49846.9131.24925.752-10.15433.66217.51823.4559.86821.8910.21515.51-31.23213.543
Other Expenses 0.48174.01-45.042-1.06-2.037-0.293-0.095-2.2660.01217.82-0.0120.045-2.0050.16-0.049-0.165-0.142-0.4160.024-0.002-0.092.9980.002
Operating Expenses 46.81633.62543.8631.41745.15247.31445.33242.0536.66356.66835.01230.60336.02732.06435.49735.70531.26441.49123.30425.02420.0321.56718.473
Operating Income 50.86932.053.499-8.608-0.585-1.906-2.6282.99716.61928.72320.0685.5664.79912.90519.92544.56673.63263.05252.46831.49929.49838.07610.508
Operating Income Ratio 0.1270.0790.01-0.038-0.003-0.006-0.0110.0140.0720.0820.0730.0290.0230.0520.0950.2010.2350.2240.250.2070.2190.240.121
Total Other Income Expenses Net -0.1880.18-0.017-34.532-20.961-0.293-0.095-2.2660.012-0.474-0.0120.045-2.0050.16-0.049-0.165-0.142-0.4160.024-0.002-0.09-0.0210.002
Income Before Tax 50.68132.233.482-43.14-21.546-2.199-2.7230.73216.63128.24920.0565.6112.79413.06519.87644.40273.48962.63652.49231.49729.40838.05510.509
Income Before Tax Ratio 0.1270.0790.01-0.19-0.105-0.007-0.0110.0030.0720.080.0730.0290.0140.0520.0950.20.2340.2230.250.2070.2180.240.121
Income Tax Expense 5.9044.387-0.781-7.667-5.14-4.103-1.702-0.311.7761.9490.1621.1220.77-0.0711.4756.53110.0329.4238.1134.2554.0844.9061.189
Net Income 44.49727.5034.22-35.473-16.4061.903-1.0211.04214.85626.319.8934.4892.02413.13718.40137.87163.45753.21244.37927.24225.32433.1499.32
Net Income Ratio 0.1120.0670.012-0.156-0.080.006-0.0040.0050.0640.0750.0720.0230.010.0520.0880.170.2020.1890.2120.1790.1880.2090.107
EPS 0.270.1660.026-0.22-0.0990.012-0.0060.0060.0910.160.120.0270.010.0790.110.230.380.260.320.110.210.270.073
EPS Diluted 0.250.160.026-0.22-0.0990.012-0.0060.0060.0910.160.120.0270.010.0790.110.230.380.260.320.110.210.270.073
EBITDA 59.84440.69916.16219.0784.8242.61236.69632.87649.14543.28346.27919.87116.84524.15330.44549.54479.4162.89753.03836.24132.05238.51813.905
EBITDA Ratio 0.150.10.0450.0840.0240.130.1510.150.2130.1230.1690.1040.0820.0960.1450.2230.2530.2240.2530.2390.2370.2420.16